Assessment of Foot Bone Quality in Patients with Type2 Diabetes Receiving Cortisone Treatment

The aim of this study was to study the effects of tepy2 diabetes (T2DM) and treatment cortisone on the foot bones. A total of 123 Iraqi men and women participated in the study (18 males and 105 females), with type 2 diabetes receiving cortisone therapy. Quantitative Ultrasound (QUS) was used to evaluate osteoporosis, speed of sound (SOS), broadband ultrasound attenuation (BUA), and calcaneus bone quality index (BQI). A dual x-ray absorptiometry (DXA) was used to determine abdominal fat percentage. The results indicate that the correlation between T-score and heel bone mineral density (BMD) for cortisone, as well as Z-score and heel BMD, is a linear relationship that has statistical significance P-value<0.0001. When we examine the relationship between calcaneal BUA and T-score we found that it is exponational with a P-value<0.0001. The correlation between calcaneal SOS and BMI is not statistically significant (P-value=0.9). Osteopenia and osteoporosis appear at the age of 43-82 years, for T2DM patients receiving cortisone therapy so was a T-score (-2.0 to -3.1). It was found that the BQI is less for patients with T2DM (62.4, 58.2), for both genders. The body mass index was (BMI) for patients with T2DM (21, 45), whereas the abdominal fat % for patients with T2DM is high for males and females (32.7, 36.4). One of the risk factors for cortisone is high blood sugar, so we noticed an increasing number of T2DM patients receiving cortisone therapy (58).